問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Digestive System Department

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation (在職)

Division of Otolaryngology

Division of Hematology & Oncology

更新時間：2023-09-19

蔡宗佑Tsai, Tsung-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years

  • D18101@mail.cmuh.org.tw

Recruiting Trial

36Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡宗佑

List

49Cases

2018-04-01 - 2020-04-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2018-04-01 - 2020-04-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2021-10-15 - 2024-06-13

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting5Sites

Terminated1Sites

2020-12-15 - 2026-01-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2022-08-01 - 2027-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2019-11-30 - 2026-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-12-04 - 2023-12-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2019-08-01 - 2021-11-03

Phase II

An Exploratory Study to Evaluate the Efficacy And Safety of HLX10, A Humanized Monoclonal Antibody Targeting Programmed Death-1 (PD-1) Protein In Chronic HepatitisB Patients

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    HLX10

Participate Sites
3Sites

Recruiting3Sites

2016-10-10 - 2022-08-31

Phase III

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABT-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis.

  • Condition/Disease

    Ulcerative colitis

  • Test Drug

    Upadacitinib(ABT-494)

Participate Sites
8Sites

Terminated6Sites

周仁偉
China Medical University Hospital-Taipei

未分科

林春吉
Taipei Veterans General Hospital

Division of Colorectal Surgery

2017-12-01 - 2020-04-01

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

  • Condition/Disease

    Crohn’s Disease

  • Test Drug

    Risankizumab(ABBV-066)

Participate Sites
6Sites

Terminated5Sites

周仁偉
China Medical University Hospital-Taipei

未分科

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB